EFTR.US Effector Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0008 USD
Close of Nov 14, 2026
0.0002 0.0008
Market cap
USD 3.76K
P/E
-
P/B
0.00x
ROE
-4,272.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2024.

Is EFTR.US undervalued?

Graham number

The Graham number of Effector Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Effector Therapeutics Inc fundamental analysis

No fundamental analysis for Effector Therapeutics Inc yet.

Effector Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Effector Therapeutics Inc

eFFECTOR Therapeutics, Inc., a biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. The company's lead product candidate includes Zotatifin, an inhibitor of eIF4A, which is in Phase 1/2 clinical trial to treat patients with solid tumors, as well as has completed Phase 2 clinical trial in combination with fulvestrant and abemaciclib to treat patients with ER+ breast cancer. It also develops Tomivosert…

Full company profile